Cheerleader E&Y fined $2 million for audit irregularities
This article was originally published in Scrip
Ernst and Young, which regularly act as cheerleader for the industry with the release of its generally positive annual life science reports, has been fined $2 million by the Public Company Accounting Oversight Board (PCAOB), the US auditing watchdog, over irregularities in auditing the accounts of dermatology specialist Medicis Pharmaceutical.
You may also be interested in...
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.
What does a good drug launch look like? Is pharma getting better at them? Which drugs are likely still to be in the top 20 in five years' time? Get the picture with Scrip's interactive infographic.